YOD1 serves as a potential prognostic biomarker for pancreatic cancer.

ABSTRACT:

Background

Ubiquitination is a basic post-translational modification of intracellular proteins and can be reversed enzymatically by DUBs (deubiquitinating enzymes). More than 90 DUBs have been identified. Among them, the deubiquitinating enzyme YOD1, a member of the ovarian tumor domain protease (OTUs) subfamily, is involved in the regulation of endoplasmic reticulum (ER)-related degradation pathways. In fact, it is reported that YOD1 is an important proliferation and metastasis-inducing gene, which can stimulate the characteristics of cancer stem cells and maintain circulating tumor cells (CTC). However, the expression level, prognostic effect and biological functional mechanism of YOD1 in pancreatic cancer are still unclear.

Results

In the GEO and TCGA databases, YOD1 mRNA

SUBMITTER: Zhang Z 

PROVIDER: S-EPMC9158148 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature